Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases

Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional payments for other indications; includes contingent R&D investment, tiered sales royalties, and a portion of investment to global development.

(Oct 2, 2025) by Patrick Till.

BURLINGAME, CA and TOKYO, JAPAN, September 30, 2025 — Hinge Bio, Inc., a privately-held biotechnology company engaged in the discovery and development of innovative medicines, announced it has entered into a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd (“Kyorin”) for development of Hinge Bio’s multispecific antibody-based therapeutic HB2198 in Japan for multiple autoimmune indications, starting with Systemic Lupus Erythematosus (“SLE”).

Per the terms of the agreement, Hinge Bio is to receive a $10 million upfront payment, is eligible to receive up to $95 million in milestone payments for the SLE indication, additional payments for other indications, and will lead global HB2198 development activities. Kyorin will fund development, regulatory, marketing and commercialization activities in Japan and contribute a portion of investment to global development. The companies have established a Joint Steering Committee (JSC) to accelerate and potentially widen the development of HB2198 to treat multiple B cell mediated autoimmune disorders.